Functional gastrointestinal disorder












intestinal disorder
Classification and external resources
MeSH D003109
[edit on Wikidata]

Functional gastrointestinal disorders (FGID), also known as disorders of gut-brain interaction include a number of separate idiopathic disorders which affect different parts of the gastrointestinal tract and involve visceral hypersensitivity and motility disturbances.[1]




Contents






  • 1 Classification


  • 2 Epidemiology


  • 3 Research


  • 4 See also


  • 5 Notes and references





Classification


Terms such as functional colonic disease (or functional bowel disorder) refer in medicine to a group of bowel disorders which are characterised by chronic abdominal complaints without a structural or biochemical cause that could explain symptoms. Other functional disorders relate to other aspects of the process of digestion.


The consensus review process of meetings and publications organised by the Rome Foundation, known as the Rome process, has helped to define the functional gastrointestinal disorders.[2] Successively, the Rome I, Rome II, Rome III and Rome IV proposed consensual classification system and terminology, as recommended by the Rome Coordinating Committee. These now include classifications appropriate for adults, children and neonates/toddlers.


The current Rome IV classification, published in 2016, is as follows:[1]


A. Esophageal Disorders



  • A1. Functional chest pain

  • A2. Functional heartburn

  • A3. Reflux hypersensitivity

  • A4. Globus

  • A5. Functional dysphagia


B. Gastroduodenal Disorders



  • B1. Functional dyspepsia

    • B1a. Postprandial distress syndrome (PDS)

    • B1b. Epigastric pain syndrome (EPS)



  • B2. Belching disorders

    • B2a. Excessive supragastric belching

    • B2b. Excessive gastric belching



  • B3. Nausea and vomiting disorders

    • B3a. Chronic nausea vomiting syndrome (CNVS)

    • B3b. Cyclic vomiting syndrome (CVS)

    • B3c. Cannabinoid hyperemesis syndrome (CHS)



  • B4. Rumination syndrome


C. Bowel Disorders



  • C1. Irritable bowel syndrome (IBS)

    • IBS with predominant constipation (IBS-C)

    • IBS with predominant diarrhea (IBS-D)

    • IBS with mixed bowel habits (IBS-M)

    • IBS unclassified (IBS-U)



  • C2. Functional constipation

  • C3. Functional diarrhea

  • C4. Functional abdominal bloating/distension

  • C5. Unspecified functional bowel disorder

  • C6. Opioid-induced constipation


D. Centrally Mediated Disorders of Gastrointestinal Pain



  • D1. Centrally mediated abdominal pain syndrome (CAPS)

  • D2. Narcotic bowel syndrome (NBS)/ Opioid-induced GI hyperalgesia


E. Gallbladder and Sphincter of Oddi disorders



  • E1. Biliary pain

    • E1a. Functional gallbladder disorder

    • E1b. Functional biliary sphincter of Oddi disorder



  • E2. Functional pancreatic sphincter of Oddi disorder


F. Anorectal Disorders



  • F1. Fecal incontinence

  • F2. Functional anorectal pain

    • F2a. Levator ani syndrome

    • F2b. Unspecified functional anorectal pain

    • F2c. Proctalgia fugax



  • F3. Functional defecation disorders

    • F3a. Inadequate defecatory propulsion

    • F3b. Dyssynergic defecation




G. Childhood Functional GI Disorders: Neonate/Toddler



  • G1. Infant regurgitation

  • G2. Rumination syndrome

  • G3. Cyclic vomiting syndrome (CVS)

  • G4. Infant colic

  • G5. Functional diarrhea

  • G6. Infant dyschezia

  • G7. Functional constipation


H. Childhood Functional GI Disorders: Child/Adolescent



  • H1. Functional nausea and vomiting disorders

    • H1a. Cyclic vomiting syndrome (CVS)

    • H1b. Functional nausea and functional vomiting

      • H1b1. Functional nausea

      • H1b2. Functional vomiting



    • H1c. Rumination syndrome

    • H1d. Aerophagia



  • H2. Functional abdominal pain disorders

    • H2a. Functional dyspepsia

      • H2a1. Postprandial distress syndrome

      • H2a2. Epigastric pain syndrome



    • H2b. Irritable bowel syndrome (IBS)

    • H2c. Abdominal migraine

    • H2d. Functional abdominal pain ‒ NOS



  • H3. Functional defecation disorders

    • H3a. Functional constipation

    • H3b. Nonretentive fecal incontinence





Epidemiology


Functional gastrointestinal disorders are very common. Globally, irritable bowel syndrome and functional dyspepsia alone may affect 16–26% of the population.[1][3]



Research


There is considerable research into the causes, diagnosis and treatments for FGIDs. Diet, microbiome, genetics, neuromuscular function and immunological response all interact.[1] A role for mast cell activation has been proposed as one of the factors.[4][5]



See also



  • Allergy

  • Food intolerance

  • Histamine intolerance



Notes and references





  1. ^ abcd Drossman DA (2016). "Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV". Gastroenterology. 150 (6): 1262–1279. doi:10.1053/j.gastro.2016.02.032. PMID 27144617..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ "Rome Foundation // Scoring Rome III Questionnaire using SAS".


  3. ^ Sperber AD, Drossman DA, Quigley EM (2012). "The global perspective on irritable bowel syndrome: a Rome Foundation-World Gastroenterology Organisation symposium". Am. J. Gastroenterol. 107 (11): 1602–9. doi:10.1038/ajg.2012.106. PMID 23160283.


  4. ^ Wouters MM, Vicario M, Santos J (2015). "The role of mast cells in functional GI disorders". Gut. 65: 155–168. doi:10.1136/gutjnl-2015-309151. PMID 26194403. It is well established that mast cell activation can generate epithelial and neuro-muscular dysfunction and promote visceral hypersensitivity and altered motility patterns in FGIDs, postoperative ileus, food allergy and inflammatory bowel disease.


  5. ^ Bashashati, M; Moossavi, S; Cremon, C; Barbaro, MR; Moraveji, S; Talmon, G; Rezaei, N; Hughes, PA; Bian, ZX; Choi, CH; Lee, OY; Coëffier, M; Chang, L; Ohman, L; Schmulson, MJ; McCallum, RW; Simren, M; Sharkey, KA; Barbara, G (January 2018). "Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis". Neurogastroenterology & Motility. 30 (1). doi:10.1111/nmo.13192. PMID 28851005. Mast cells and CD3+ T cells are increased in colonic biopsies of patients with IBS vs non-inflamed controls











-

Popular posts from this blog

Lambaréné

Image
Place in Moyen-Ogooué, Gabon Lambaréné Street in Lambaréné Lambaréné Location in Gabon Coordinates: 0°41′18″S 10°13′55″E  /  0.68833°S 10.23194°E  / -0.68833; 10.23194 Coordinates: 0°41′18″S 10°13′55″E  /  0.68833°S 10.23194°E  / -0.68833; 10.23194 Country   Gabon Province Moyen-Ogooué Population (2013 census)  • Total 38,775 Lambaréné is a town and the capital of Moyen-Ogooué in Gabon. With a population of 38,775 as of 2013, it is located 75 kilometres south of the equator. Lambaréné is based in the Central African Rainforest at the river Ogooué. This river divides the city into 3 districts: Rive Gauche, Ile Lambaréné and Rive Droite. The Albert Schweitzer Hospital and the districts Adouma and Abongo are located on Rive Droite. The districts Atongowanga, Sahoty, Dakar, Grand Village, Château, Lalala and Bordamur build the Ile Lambaréné. The majority of the people in Lambaréné live in the district Isaac located on Rive Gauche. This distr
Read more

Chris Pine

Image
Not to be confused with Christopher Pyne or Chris Pyne. Chris Pine Pine in 2018 Born Christopher Whitelaw Pine ( 1980-08-26 ) August 26, 1980 (age 38) Los Angeles, California, U.S. Alma mater UC Berkeley Occupation Actor Years active 2003–present Parent(s) Robert Pine Gwynne Gilford Relatives Anne Gwynne (grandmother) Christopher Whitelaw Pine (born August 26, 1980) [1] [2] is an American actor. Pine made his feature debut as Lord Devereaux in The Princess Diaries 2: Royal Engagement (2004). He is known for playing James T. Kirk in the Star Trek reboot film series (2009–2016), Will in Unstoppable (2010), Cinderella's Prince in Into the Woods (2014), Jack Ryan in Jack Ryan: Shadow Recruit (2014), Toby Howard in Hell or High Water (2016), Bernie Webber in The Finest Hours (2016), Steve Trevor in Wonder Woman (2017), and Dr. Alexander Murry in A Wrinkle in Time (2018). Contents 1 Early life 2 Career 2.1 2003–200
Read more

Kashihara Line

Image
Kashihara Line   B   A Kashihara Line train passing Yakushi-ji temple Overview Native name 橿原線 Type Commuter rail System Kintetsu Railway Locale Nara, Nara, Japan Yamtokoriyama, Nara, Japan Tenri, Nara, Japan Kawanishi, Nara, Japan Miyake, Nara, Japan Tawaramoto, Nara, Japan Kashihara , Nara, Japan Termini Yamato-Saidaiji Kashiharajingu-mae Stations 17 Operation Opened April 1, 1921 ; 98 years ago  ( 1921-04-01 ) Owner Kintetsu Railway Character Commuter rail Technical Line length 23.8 km (14.8 mi) Track gauge 1,435 mm ( 4 ft  8   1 ⁄ 2  in ) Minimum radius 240 m Electrification 1,500 V DC Overhead lines Operating speed 100 km/h (60 mph) [1] The Kashihara Line ( 橿原線 , Kashihara-sen ) is a 23.8 km (14.8 mi) north-south bound railway line in Nara Prefecture, Japan, owned and operated by the Kintetsu Railway, a private railway operator. It connects Yamato-Saidaiji Station and Kashiharajingu
Read more